Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:KRTX Karuna Therapeutics (KRTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Karuna Therapeutics Stock (NASDAQ:KRTX) 30 days 90 days 365 days Advanced Chart Ad Banyan Hill PublishingDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. Get Karuna Therapeutics alerts:Sign Up Key Stats Today's Range$329.83▼$329.8350-Day Range$313.97▼$329.8352-Week Range$158.38▼$329.99Volume5 shsAverage Volume832,048 shsMarket Capitalization$12.58 billionP/E RatioN/ADividend YieldN/APrice Target$330.00Consensus RatingHold Company OverviewKaruna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Read More… Receive KRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KRTX Stock News HeadlinesThis FDA-approved drug promises a new way to treat schizophreniaSeptember 30, 2024 | msn.comBMS wins approval for schizophrenia drug acquired from KarunaSeptember 27, 2024 | msn.comMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.December 25, 2024 | Brownstone Research (Ad)Bristol Myers to Purchase KarunaSeptember 13, 2024 | msn.comS&P 500 Q1 earnings estimated growth improves; stocks up for weekApril 26, 2024 | investing.comBristol Myers posts quarterly loss, lays out $1.5 billion cost-saving planApril 25, 2024 | investing.comAfter Karuna's acquisition, former CEO lands new gig at Cambridge biotechApril 22, 2024 | bizjournals.comSeaport Therapeutics has $100 million to develop new ways to treat mental disordersApril 9, 2024 | msn.comSee More Headlines KRTX Stock Analysis - Frequently Asked Questions How were Karuna Therapeutics' earnings last quarter? Karuna Therapeutics, Inc. (NASDAQ:KRTX) issued its quarterly earnings data on Thursday, February, 22nd. The company reported ($3.01) earnings per share for the quarter, missing the consensus estimate of ($2.65) by $0.36. The company's revenue for the quarter was down 100.0% compared to the same quarter last year. When did Karuna Therapeutics IPO? Karuna Therapeutics (KRTX) raised $70 million in an initial public offering (IPO) on Friday, June 28th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What other stocks do shareholders of Karuna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Karuna Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Palo Alto Networks (PANW), Salesforce (CRM) and Netflix (NFLX). Company Calendar Last Earnings2/22/2024Today12/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KRTX CUSIPN/A CIK1771917 Webkarunatx.com Phone(857) 449-2244FaxN/AEmployees339Year FoundedN/APrice Target and Rating Average Stock Price Target$330.00 High Stock Price Target$330.00 Low Stock Price Target$330.00 Potential Upside/Downside+0.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($11.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-433,680,000.00 Net MarginsN/A Pretax Margin-66,209.48% Return on Equity-31.63% Return on Assets-30.38% Debt Debt-to-Equity RatioN/A Current Ratio19.31 Quick Ratio19.31 Sales & Book Value Annual Sales$654,000.00 Price / Sales19,239.07 Cash FlowN/A Price / Cash FlowN/A Book Value$33.24 per share Price / Book9.92Miscellaneous Outstanding Shares38,148,000Free Float33,157,000Market Cap$12.58 billion OptionableOptionable Beta1.18 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NASDAQ:KRTX) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karuna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karuna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.